Nkarta, Inc.
- Home
- Companies
- Nkarta, Inc.
- Products
- Nkarta - Model NKG2D - NKX101 - ...
Nkarta - Model NKG2D - NKX101 - Activating Receptor
FromNkarta, Inc.
OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15.
Most popular related searches
tumor targeting
hematologic malignancies
clinical trial
natural killer cell
solid tumor
cancer cell
patient enrollment
hematologic
hematology
tumor activity
- Opportunity to treat a variety of hematologic malignancies and solid tumors
- Targets of NKG2D are selectively over-expressed in cancer cells
- Native NK activation and tumor killing largely driven by NKG2D receptor
- For NKX101, expression of the activating chimeric receptor is increased 10X relative to nonengineered NK cells
- OX40 selected based on superiority vs. other costimulatory domains
- A Phase 1 clinical trial of NKX101 is currently enrolling patients.
